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Introduction:Microcirculatory alterations in sepsis are associated with increased morbidity and mortality. These
alterations occur despite macrohemodynamic resuscitation. Alternative pro-microcirculatory strategies, includ-
ing vasodilatory drugs, have been suggested to improve capillary blood ﬂow. Ketanserin, a serotonin receptor an-
tagonist, is an attractive candidate because of its vasodilatory, antithrombotic, and anti-inﬂammatory effects.
Methods: This is an open-label pilot study on the effect of ketanserin administration on microcirculatory alter-
ations in septic shock, deﬁned as microvascular ﬂow index (MFI) ≤ 2.5 after a strict macrohemodynamic resus-
citation protocol. Sidestream dark-ﬁeld imaging was applied to assess the microcirculation. A stepwise
incremental dose regiment was applied until an MFI N 2.9, the primary end point, was reached.
Results: Ten patients (Acute Physiology and Chronic Health Evaluation IV scores of 115 [100-136])were included.
Baseline MFI was 1.71 (1.31-2.32) and was signiﬁcantly increasing to 2.96 (2.54-3.00; P = .021) during the
ketanserin infusion. The total ketanserin dose was 0.09 (0.08-0.13) mg/kg per patient in 60 (30-60) minutes.
In 3 patients (30%), the ketanserin infusion was discontinued due to refractory hypotension.
Conclusion:An improvement inmicrocirculatory perfusionwas observed during ketanserin administration in pa-
tients with septic shock after macrohemodynamic resuscitation. This ﬁnding needs further exploration in a
placebo-controlled setting.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The microcirculation in sepsis is characterized by heterogeneous al-
terations in both ﬂow and vessel density [1]. A consistent observation
is the absence of a clear correlation betweenmicrocirculatory alterations
and systemic hemodynamic parameters despite macrohemodynamic
resuscitation [2]. Because these microcirculatory alterations are associ-
ated with increased morbidity and mortality, the microcirculation
appears to be an appealing target in sepsis resuscitation [3,4]. Main
aim of microcirculatory resuscitation is capillary recruitment in order
to improve oxygen transport to the cells [1]. The classical paradigm is
to increase perfusion pressure in order to enhance organ perfusion.
However, since the introduction of in vivo microscopy at the bedside,
it has become clear that augmenting blood pressure will not have
beneﬁcial effects onmicrocirculatory perfusion per se [5–9]. Alternative-
ly, treatment could be directed at opening up themicrocirculation by re-
cruitment of weak microcirculatory units [10,11]. Nevertheless, studiespmans).
. This is an open access article underwith different types of vasodilators have not yielded unequivocal results
either [12–18]. Therefore, the search for a pro-microcirculatory resusci-
tation strategy continues. Ketanserin could be an attractive candidate for
recruitment of the microcirculation: in addition to vasodilatory proper-
ties via serotonin (5HT) receptor 5HT2a and the adrenergic α1-receptor,
ketanserin also attenuates thrombocyte aggregation and could therefore
improve the microcirculation by preventing formation of occlusive
microthrombi [19–22]. Furthermore, serotonin receptor antagonists
are reported to have beneﬁcial effects on cytokine proﬁles and
leukocyte-endothelium interactions in animal sepsis models [23–25].
In cardiac surgery, ketanserin treatment lowered the incidence of
endotoxemia [26]. Data on the direct effect of ketanserin on the
human microcirculation are limited: in postcardiac surgery, hyperten-
sion ketanserin lowered blood pressure, without impairment of sublin-
gual microcirculatory ﬂow or vessel density. An improvement of
digital capillary blood ﬂow was observed in patients with Raynaud
phenomenon after ketanserin treatment [27–29]. The aim of the
present pilot study is to investigate the effect of a stepwise dose ﬁnding
schedule of intravenous ketanserin on compromised sublingual micro-
circulation in patients with severe sepsis and septic shock after initial
macrohemodynamic resuscitation.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Ketanserin trial scheme. Each step consists of an intravenous bolus followedby a continuous intravenous infusion for 30minutes. T indicates time; T=0minutes denotes the start of
the study. Before step 1 and after each step, SDF measurements are repeated. In case of a capillary MFI ≤2.5 after a step, the ketanserin dose is increased according to this scheme.
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2.1. Study design
This study is an open-label dose ﬁnding pilot study in 10 patients
on the effect of ketanserin on sublingual microcirculatory alterations
in patients 18 years or older with severe sepsis and septic shock
(NCT01329887, ClinicalTrials.gov). Inclusion was characterized by
2 main criteria: (1) fulﬁllment of international criteria for severe
sepsis or septic shock [30] and (2) persistence of microcirculatory alter-
ations after standardized resuscitation (see below), deﬁned as a micro-
vascular ﬂow index (MFI) ≤ 2.5 in small vessels (b20 μm). Exclusion
criteria were age less than 18 years, prolonged corrected QT interval,
or recent oropharyngeal surgery interfering with Sidestream dark-
ﬁeld (SDF) measurements. The study was approved by the local ethics
committee (Medical Research Ethics Committee, Medical Center Leeu-
warden, the Netherlands). Written informed consent was obtained
from all included patients or their legal representative in accordance
with local legislation.Table 1
Baseline patient characteristics
Age (y) 63 (54-72)
Male, n (%) 5 (50)
APACHE II 30 (25-34)
Predicted mortality (APACHE II; %) 75 (65-87)
APACHE IV 115 (100-136)
Predicted mortality (APACHE IV; %) 65 (40-85)
SOFA 11 (8-14)
Sepsis type, n (%)
Abdominal sepsis 7 (70)
Pneumosepsis 1 (10)
Necrotizing fasciitis 1 (10)
Meningitis 1 (10)
Conﬁrmed infection, n (%) 8 (80)
LOS ICU (d) 8 (3-26)
LOS hospital (d) 24 (23-50)
ICU mortality, n (%) 5 (50)
Hospital mortality, n (%) 5 (50)
Highest arterial lactate before inclusion (mmol/L) 5.5 (4.3-7.6)
Fluid balance (0-24 h after ICU admission; mL) 5450 (3658-10450)
Steroids, n (%) 7 (70)
Mechanical ventilation, n (%) 10 (100)
PEEP (cm H2O) 12 (10-14)
FIO2 (%) 50 (40-75)
Renal replacement therapy, n (%) 4 (40)
Values are median (interquartile range) unless stated otherwise. SOFA indicates Sequen-
tial Organ Failure Assessment; LOS, length of stay; PEEP, positive end-expiratory pressure;
FIO2, fraction of inspired oxygen; n, number.2.2. Sidestream dark-ﬁeld imaging and analysis
Sidestream dark-ﬁeld imaging and subsequent image analysis were
performed in line with international consensus [31,32]. An SDF camera
(MicroScan; MicroVision Medical, Amsterdam, the Netherlands) is a
form of handheld intravital microscopy enabling direct visualization of
the microcirculation [33]. In short, the SDF camera emits stroboscopic
green light with a wavelength (530 nm) within the absorption spec-
trum of hemoglobin, thereby depicting erythrocytes as black cells on
the screen. The area of visualization is 1 mm2.
Ofﬂine software-assisted analysis (AVA 3.0; MicroVision Medical)
yields the semiquantitative MFI, ranging from 0 (no ﬂow) to 3 (contin-
uous ﬂow), and percentage of perfused vessels (PPVs), providing infor-
mation on convection, whereas total vessel density (TVD) and perfused
vessel density (PVD) provide information ondiffusion [34]. Heterogene-
ity index was calculated as the difference between the highest and the
lowest quadrant MFI divided by the average MFI of all sublingual sites
[35]. Vessels were separated into large (mostly venules) and small
(mostly capillaries) using a diameter cutoff value of 20 μm. Initial anal-
ysis of images during the screening process of patients was performed
at the bedside by eyeballing MFI. Measurements were performed by a
small group of dedicated researchers. The MFI was calculated as the
mean for 3 different sublingual regions. Bedside assessment of MFI has
good agreement with ofﬂine analysis [36]. Subsequent detailed ofﬂine
analysis was performed blinded and in a randomized order to prevent
coupling between images.
2.3. Resuscitation
Resuscitation was performed in linewith a strict protocol aiming for
the following resuscitation goals: a mean arterial pressure (MAP) of
60 mm Hg or greater, a mixed or central venous oxygen saturation
(S(c)vO2) at least 70% and a cardiac index (CI) at least 2.5 L min−1
m−2. This protocol reﬂects standard practice in our intensive care unit
(ICU) [13,37]. Systemic hemodynamic monitoring consisted of continu-
ous invasive monitoring of arterial blood pressure and continuous
cardiac output and SvO2 measurements using a pulmonary artery cath-
eter (Vigilance; Edwards Lifesciences, Saint-Prex, Switzerland) or a
pulse contour analysis system (PiCCO; Pulsion Medical Systems AG,
Munich, Germany) in combination with repeated S(c)vO2 measure-
ments via a central venous line in the jugular or subclavian vein.
Stepwise goal-directed protocolized resuscitation consisted of (1) re-
peated infusions of at least 250 mL of crystalloids, colloids, or blood
products (no albumin because of high protein binding of ketanserin),
until the increase in stroke volume was less than 10%. Crystalloids
were the resuscitation ﬂuids of choice; colloids and blood products
were administered at the discretion of the attending physician, with
Fig. 2. Small-vessel (b20 μm)MFI at baseline and after ketanserin administration for all patients (boxplots) and for individual patients without refractory hypotension (n= 7) and with
refractory hypotension (n = 3). AU indicates arbitrary units.
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25%; (2) treatment of inadequate systemic oxygen supply (deﬁned as CI
b 2.5 Lmin−1 m−2 or S(c)vO2 b 70%)with dopamine or dobutamine ad-
ministered at up to 10 μg/kg per minute and additional enoximone in
case of an inadequate response to dopamine or dobutamine; and
(3) treatment with norepinephrine in case of MAP b 60mmHg despite
the aforementioned steps. In case of hypotension despite vasopressor
support, hydrocortisone at a maximum dose of 300 mg/d was adminis-
tered. During the study period, therapeutic goals and resuscitation pro-
tocol remained unchanged.
2.4. Screening of eligible patients
After fulﬁllment of the resuscitation end points, eligible patients
were screened for inclusion. In case bedside SDF assessment revealed
a small-vessel MFI ≤ 2.5, patients were included for this study after
obtaining informed consent of the patient or legal representative.
2.5. Ketanserin administration and data collection
In case of a small-vessel MFI ≤ 2.5 after fulﬁllment of the above-
mentioned resuscitation goals, baseline measurements (SDF, hemody-
namics, blood samples) were made. After the baseline measurements,
intravenous ketanserin infusion was started following the scheme
in Fig. 1. Each step consisted of a ketanserin bolus, followed by a
30-minute continuous infusion, with the ﬁrst step being a bolus of
0.015 mg/kg and a 30-minute continuous infusion of 0.03 mg/kg per
hour. In case of hypotension (MAP b 60 mm Hg for N1 minute) during
ketanserin administration, patients were resuscitated following the
standard resuscitation protocol. In case of MAP b 60 mm Hg for more
than 10 minutes or MAP b 50 mm Hg for more than 5 minutes despite
resuscitation, the ketanserin infusion was discontinued (refractoryTable 2
Microcirculatory parameters before and after ketanserin administration
Baseline After ketanserin P
MFI (small vessels; AU) 1.71 (1.13-2.32) 2.96 (2.54-3.00) .021
MFI (large vessels; AU) 2.66 (2.23-2.87) 3.00 (2.79-3.00) .080
TVD (small vessels; mm/mm2) 23.52 (19.78-25.70) 22.31 (19.76-25.42) .646
TVD (large vessels; mm/mm2) 3.57 (2.52-4.95) 4.76 (4.35-5.24) .139
PVD (small vessels; mm/mm2) 18.64 (11.14-21.62) 20.49 (17.06-23.44) .241
PVD (large vessels; mm/mm2) 3.49 (3.70-5.75) 4.76 (4.34-5.24) .445
PPV (small vessels) 0.78 (0.55-0.90) 0.92 (0.78-0.93) .037
Heterogeneity index (small
vessels)
1.34 (0.57-2.35) 0.17 (0.00-0.49) .021
Small vessels, vessels less than 20 μm. AU indicates arbitrary units. Data are expressed as
median (interquartile range) unless stated otherwise.hypotension). After each step, data on hemodynamics, applied therapy,
and arterial blood gas analysis were collected. Furthermore, SDF mea-
surements of the sublingual microcirculation were acquired. In case of
a capillary MFI b 2.9, the ketanserin dose was increased following the
scheme in Fig. 1, with a maximum study period of 2 hours (4 steps).
The ketanserin infusion was stopped in case of an MFI ≥ 2.9, refractory
hypotension (see above), or after completion of all 4 steps.
2.6. Statistical analysis
Because this is a pilot study, a true sample size calculation was
not applicable. The sample size was in accordance with comparable
previous studies [12,18]. Primary aim was to describe the changes in
microcirculation observed during ketanserin administration. Secondary
end points were the administered ketanserin dose and incidence of
(refractory) hypotension. Whenever appropriate, a nonparametric test
(Wilcoxon signed-rank test) was used to test for differences between
time points. Data are presented as median (interquartile range).
3. Results
3.1. Patients
Of 60 screened patients, 15 patients fulﬁlled the entry criteria of an
MFI ≤ 2.5. Five denied informed consent. Ten patients with Acute Phys-
iology and Chronic Health Evaluation IV (APACHE IV) scores of 115
(100-136), Sequential Organ Failure Assessment scores of 11 (8-14),
and highest lactate levels before inclusion of 5.5 (4.3-7.9) mmol/L
were included after bedside conﬁrmation of a small vessel MFI ≤ 2.5
(Table 1). Most patients (70%) were admitted because of abdominal
sepsis. All patients but one fulﬁlled the criteria of septic shock, and in
80% of patients, positive cultures conﬁrmed the presence of an infection.
The ICUmortalitywas 50% for an APACHE IV–predictedmortality of 65%
(40%-85%). The average total ketanserin dose during the study period
was 7.5 (6.2-9.8) mg per patient (0.09 [0.08-0.13] mg/kg) in 60 (30-
60)minutes. Five patients fulﬁlled stop criteria within 2 doses and 2 pa-
tients within 4 doses of ketanserin.
3.2. Microcirculation
Before the start of the ketanserin infusion, small vessel MFI was 1.71
(1.13-2.32). During the ketanserin infusion,MFI increased to 2.96 (2.54-
3.00; P = .021). In 6 of 7 patients without refractory hypotension, MFI
improved to MFI ≥ 2.9 between T0 and the end of the ketanserin infu-
sion. Microvascular ﬂow index also increased in 2 of 3 patients with re-
fractory hypotension (Fig. 2). Heterogeneity index over the course of
Fig. 3. Heterogeneity index (HI), PPV, TVD, and PVD for small (s) vessels (b20 μm) before and after ketanserin administration.
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surements (1.34 [0.57-2.35) vs 0.17 [0.00-0.49], P= .021). Small vessel
PPV increased (0.78 [0.55-0.90] vs 0.92 [0.78-0.93], P = .037). Vessel
densities for both small and large vessels and large vessel MFI did not
show any signiﬁcant changes (Table 2; Figs. 3 and 4).
3.3. Macrohemodynamics
Over the course of the ketanserin infusion, MAP was lowered by 6
(1-11) mmHg leading to increases in vasopressor use in 6 patients. Av-
erage norepinephrine dosage increased from 0.19 (0.11-0.34) to 0.21
(0.19-0.36; P = .026). In 3 patients (30%), the study was discontinued
due to refractory hypotension. One of these patients had a MAP of
44 mm Hg at baseline, but remained unresponsive to further therapy.
Inotropic therapy was restricted to dobutamine in 1 patient and
enoximone in 2 patients. Average ﬂuid administration during the
study period was 550 (190-1275) mL. No signiﬁcant changes in heart
rate, CI, lactate levels, and central venous pressure (CVP)were observed,
whereas S(c)vO2 signiﬁcantly increased from 71% (60%-78%) to 75%
(69%-81%; P = .024). Central-to-toe temperature gradient decreased
from 8.6°C (5.1-10.2°C) to 7.4°C (4.6-9.0°C; P = .012; see Table 3 and
Fig. 5 for an overview of macrohemodynamic data).
4. Discussion
Main ﬁnding of the present study is thatmicrocirculatory blood ﬂow
but not vessel density increases during ketanserin administration in
septic patients with a small-vessel MFI ≤ 2.5 at baseline. The presence
of profound microvascular alterations despite macrohemodynamic re-
suscitation is in line with previous reports [3,13,15]. Albeit slightlylower as predicted based on APACHE IV scores, the considerablemortal-
ity underlines the severity of disease.
At the level of the macrocirculation, ketanserin administration was
accompanied by a decrease in blood pressure necessitating increases
in vasopressor dose in 60% and dictating discontinuation of the study
drug in 3 (30%) patients. It is difﬁcult to determine whether this could
be due to a direct (vasodilatory) effect of ketanserin or that other factors
might have played a role. Ketanserin might have unmasked hypovole-
mia despite fulﬁllment of resuscitation end points in 2 of 3 patients, as
illustrated by the considerable amount of ﬂuids that was administered
during the study period in most patients. Interestingly, the one patient
inwhomMAPwas less than 60mmHgbefore the start of the ketanserin
infusion managed to increase MFI to 3 despite persistence of refractory
hypotension. Taken together with the signiﬁcant decreases in blood
pressure during the study period, this demonstrates the absence of a lin-
ear association between hypotension and microcirculatory alterations.
Ketanserin may inﬂuence microcirculatory perfusion in several
ways. Ketanserin is a selective 5HT2a-receptor antagonist as well as an
α1-receptor antagonist. Besides direct vasodilation by antagonism of
α1-receptors, ketanserin can also induce effects on themicrocirculation
via the 5HT2a-receptor, 1 of 14 serotonin receptor subtypes [19,38]. Se-
rotonin in the peripheral circulation is released by activated platelets
[39]. Platelet activation appears to play a pivotal role in impairment of
microcirculatory perfusion in sepsis [40,41]. Inﬂammatory stimuli lead
to secretion of P-selectin, VonWillebrand factor, and serotonin, causing
the platelets to adhere to the endothelium [42,43]. Ketanserin is known
for attenuating 5HT2a-mediated platelet aggregation and might there-
fore prevent the formation of occlusive microthrombi [44,45].
Serotonin has a complex variety of cardiovascular effects, mediated
by several subtypes of the 5HT-receptor. It is a potent vasoconstrictor
by stimulating 5HT2a-mediated vasoconstriction of vascular smooth
Fig. 4.Microvascular ﬂow index, TVD, and PVD for large (L) vessels (N20 μm) before and after ketanserin administration.
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thelium dependent vasodilation by increased nitric oxide (NO) release
[46]. Therefore, ketanserin can induce vasodilation by blockage of
5HT2a receptors, whereas 5HT2b-mediated vasodilation due to endothe-
lial NO release is preserved. The resulting action of serotonin depends
on the receptor subtype involved as well as the local conditions such
as endothelial damage or hypoxia [46]. Under conditions of hypoxia,
NO scavenging by erythrocytes can lead to profound serotonin induced
vasoconstriction [47].
Data on the effects of ketanserin in human sepsis are limited. In car-
diac surgery, treatment with ketanserin attenuated endotoxemia [26].
The only study applying direct in vivo microscopy of the microcircula-
tion during ketanserin administration was performed in postcardiacTable 3
Macrohemodynamic parameters, dopamine and norepinephrine dose, and lactate levels
before and after ketanserin administration
Baseline After ketanserin P
Heart rate (beats/min) 110 (99-130) 109 (103-131) .683
MAP (mm Hg) 66 (60-77) 60 (53-64) .028
Central venous pressure (mm Hg) 13 (8-15) 10 (5-16) .160
S(c)vO2 (%) 71 (60-78) 75 (69-81) .024
CI (L min−1 m−2) 3.0 (2.3-3.9) 2.9 (2.3-3.6) .474
Central-to-toe temperature
gradient (°C)
8.6 (5.1-10.2) 7.4 (4.6-9.0) .012
Arterial lactate (mmol/L) 4.7 (2.7-6.5) 4.1 (1.8-6.5) .609
Dopamine dose (μg kg−1 min−1) n = 4 n = 5 .317
5.7 (2.0-9.1) 3.3 (2.1-8.8)
Norepinephrine dose (μg kg−1 min−1) n = 9 n = 9 .027
0.19 (0.11-0.34) 0.21 (0.19-0.36)
N indicates number of patients. Data are expressed asmedian (interquartile range) unless
stated otherwise.surgery hypertension. Ketanserin lowered blood pressure with a con-
comitant increase in large-vessel PVD, whereas small PVD and small-
vessel MFI remained unchanged. This was interpreted as shunting as a
result of ketanserin administration [27]. Although we did not observe
signs of shunting at the level of the microcirculation in our patients,
the signiﬁcant increase in S(c)vO2 together with stabile CI and lactate
levels and a lower central-to-toe temperature gradient could also indi-
cate a shunting effect without an increase in oxygen consumption at
the level of the microcirculation.
Being the ﬁrst study on the effect of ketanserin on the sublingualmi-
crocirculation in septic patients, no data on potentially effective doses
are available. Therefore, we decided to titrate the ketanserin dose
based on microcirculatory response. Inclusion of patients with a com-
promised microcirculatory ﬂow allows for a better evaluation of the ef-
fect of ketanserin: an MFI of 3 cannot be improved further. Although
MFI has been validated for bedside assessment, one of the patients
had an MFI of 3 at inclusion [36].
Moreover, a stepwise increase in the dose allowed for more
safety with respect to inducing hypotension. Although hypotension
can result from numerous causes during septic shock, administration
of a vasodilator should of course be done with caution. Indeed, in 3 of
10 patients, refractory hypotension occurred. In these cases, ketanserin
might have unmasked hypovolemia despite resuscitation. However, in
2 of 3 patients, hypotension persisted despite discontinuation of the
ketanserin infusion.
Themajor limitation of this pilot study is its open-label design with-
out a placebo group and a limited number of patients. It is difﬁcult to de-
termine whether the observed increase in MFI is due to the ketanserin
infusion or other factors, such as timing. Our ﬁndings of improvement
of microcirculatory perfusion ﬁt in with other open-label studies on
the effects of nitroglycerin and dobutamine [12,18]. However, no
Fig. 5. Systolic bloodpressure (SBP),MAP, anddiastolic bloodpressure (DBP), S(c)vO2, arterial lactate levels, central-to-toe temperature (deltaT), andCI before and after ketanserin administration.
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randomized, placebo-controlled setting [13,16]. As the endothelium in
sepsis remains responsive to vasodilating stimuli, maximal endogenous
precapillary smooth muscle relaxation could be a factor to take into ac-
count when applying vasodilators with both nonendothelium aswell as
endothelium mediated properties [15,18]. This is illustrated by the
blunting of any microcirculatory effects of vasodilation in the context
of thoracic epidural analgesia after hypervolemic hemodilution [48].
Further experimental research is needed to elucidate the position of va-
sodilators in microcirculatory recruitment.
Being a pilot study, we decided to include patients with impaired
microvascular ﬂow after fulﬁllment of macrohemodynamic end points.
Therefore, it is difﬁcult to extrapolate our ﬁndings to patients with less
severe disease. On top of that, little is known about pharmacokinetics
and pharmacodynamics of ketanserin in sepsis. In nonseptic patients,
ketanserin displays a nonlinear elimination with sequential half-lives
of 8 minutes, 2 hours, and 14 hours, because of the partly reoxidation
of one of thenonpharmacologically activemetabolites to ketanserin. Re-
duced hepatic clearance, but not renal impairment, can inﬂuence
ketanserin bioavailability, which can be of importance in our study
group. Doses in our study were below the doses reported to be safe in
patientswith nonseptic organ impairment [19]. Spronk et al [12] report-
ed the use of 2 mg/h of ketanserin in sepsis before administering nitro-
glycerin, but no information on the exact indications for starting the
drug was provided.
The considerable incidence of hypotension raises questions
about the safety of using this vasodilator in severely ill patients.
By using a stepwise dosing protocol, we aimed to ﬁnd the lowest
possible dose for inducing capillary recruitment in order to minimizechances of refractory hypotension. Of course, optimal conventional
macrohemodynamic resuscitation remains the cornerstone of patient
care in sepsis, and therefore, every effort should be made to avoid
suboptimal macrohemodynamic resuscitation during administration
of a vasodilator.
In conclusion, the observed improvement in microcirculatory perfu-
sion during short-term ketanserin administration could ﬁt in with the
observed effects in (animal) experiments on platelet aggregation, vaso-
dilation, inducible NO synthase, baroreceptor reﬂex, and cytokine pro-
ﬁles. Furthermore, this study provides a framework for the ketanserin
dose that might lead to capillary recruitment. Although the open-label
design, the small number of patients, and the considerable incidence
of refractory hypotension do not allow strong conclusions, we believe
that further elaboration of ketanserin-induced promotion of microcir-
culatory blood ﬂow deserves exploration in a randomized placebo-
controlled setting.References
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